Discontinue treatment if NMS occurs; in patients w/ severe neutropenia (ANC <1,000/mm
3) & follow their WBC counts until recovery. Consider discontinuation if signs & symptoms of tardive dyskinesia appear; at 1st sign of clinically significant decline in WBC in absence of other causative factors. Consider dose reduction or stopping treatment if compulsive urges develop. Not for treatment of dementia-related psychosis. Not to inj both inj, if initiating w/ the 2-inj start, concomitantly into same deltoid or gluteal muscle. Cerebrovascular adverse reactions eg, stroke, transient ischemic attack; tardive dyskinesia; hyperglycemia/DM, dyslipidemia, wt gain; pathological gambling & compulsive behaviors; orthostatic hypotension; somnolence, postural hypotension, motor & sensory instability leading to falls & fractures or other injuries; leukopenia, neutropenia, agranulocytosis; disruption of body's ability to reduce core body temp; esophageal dysmotility & aspiration. Patients w/ history of seizures or conditions that lower seizure threshold; at risk for aspiration pneumonia. Monitor worsening of glucose control; symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, & weakness; wt; fever or other symptoms or signs of infection in patients w/ clinically significant neutropenia. Perform fasting blood glucose testing in patients w/ risk factors for DM at the beginning & periodically during treatment; CBC in patients w/ history of clinically significant low WBC/ANC or drug-induced leukopenia/neutropenia during 1st few mth of therapy. May impair ability to drive or operate machinery. Pregnancy & lactation. May decrease milk supply in post-partum period if exposed during pregnancy. Risk of extrapyramidal &/or w/drawal symptoms in neonates exposed to antipsychotic drugs during 3rd trimester following delivery. Monitor breastfed infant for dehydration & lack of appropriate wt gain. Childn ≤18 yr. Elderly w/ dementia-related psychosis.
Sign Out
Continue with Google
Sign Up With Email
Already a member?
Sign In
